Opthea Full Year 2024 Earnings: Misses Expectations

Opthea (ASX:OPT) Full Year 2024 Results

Key Financial Results

• Net loss: US$220.2m (loss widened by 55% from FY 2023).
• US$0.34 loss per share (further deteriorated from US$0.32 loss in FY 2023).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Opthea Revenues and Earnings Miss Expectations

Revenue missed analyst estimates by 50%. Earnings per share (EPS) also missed analyst estimates by 25%.

Looking ahead, revenue is forecast to grow 56% p.a. on average during the next 3 years, compared to a 7.5% growth forecast for the Biotechs industry in Australia.

Performance of the Australian Biotechs industry.

The company's share price is broadly unchanged from a week ago.

Risk Analysis

We should say that we've discovered 4 warning signs for Opthea (3 don't sit too well with us!) that you should be aware of before investing here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.